Abstract
Increases in abundance of cathepsin B transcript and protein correlate with increases in tumor grade and alterations in subcellular localization and activity of cathepsin B. The enzyme is able to degrade the components of the extracellular matrix (ECM) and activate other proteases capable of degrading ECM. To investigate the role played by this protease in the invasion of brain tumor cells, we transfected SNB19 human glioblastoma cells with a plasmid containing cathepsin B cDNA in antisense orientation. Control cells were transfected with vector alone. Clones expressing antisense cathepsin B cDNA exhibited significant reductions in cathepsin B mRNA, enzyme activity and protein compared to controls. Matrigel Invasion assay showed that the antisense-transfected cells had a markedly diminished invasiveness compared with controls. When tumor spheroids containing antisense transfected SNB19 cells expressing reduced cathepsin B were co-cultured with fetal rat brain aggregates, invasion of fetal rat brain aggregates was significantly reduced. Green Fluorescent Protein (GFP) expressing parental cells and antisense transfectants were generated for detection in mouse brain tissue without any post-chemical treatment. Intracerebral injection of SNB19 stable antisense transfectants resulted in reduced tumor formation in nude mice. These results strongly support a role for cathepsin B in the invasiveness of human glioblastoma cells and suggest cathepsin B antisense may prove useful in cancer therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA . 1993 Cancer 71: 1368–1383
Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF . 1992 Biochem. J. 282: 273–278
Cao L, Taggart RT, Berquin IM, Moin K, Fong D, Sloane BF . 1994 Gene 139: 163–169
Coulibaly S, Schwihla H, Abrahamson M, Albini A, Cerni C, Clark JL, Ng KM, Katunuma N, Schlappack O, Glossl J, Mach L . 1999 Int. J. Cancer 83: 526–531
Cox JL, Sexton PS, Green TJ, Darmani NA . 1999 Melanoma Res. 9: 369–374
Duffy MJ . 1992 Clin. Exp. Metastasis 10: 145–155
Demchik LL, Sameni M, Nelson K, Mikkelsen T, Sloane BF . 1999 Int. J. Dev. Neurosci. 17: 483–494
Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG . 1998 J. Clin. Oncol. 16: 1013–1021
Friedrich B, Jung K, Lein M, Turk I, Rudolph B, Hampel G, Schnorr D, Loening SA . 1999 Eur. J. Cancer 35: 138–144
Go Y, Chintala SK, Oka K, Gokaslan Z, Sawaya R, Rao JS . 1996 Cancer Lett. 110: 225–231
Goldbrunner RH, Berstein JJ, Tonn JC . 1998 Microscopy Res. Tech. 43: 250–257
Gunning P, Leavitt J, Muscat G, Ng SY, Kedes L . 1987 Proc. Natl. Acad. Sci. USA 84: 4831–4835
Heidtmann HH, Salge U, Abrahamson M, Bencina M, Kastelic L, Kopitar-Jerala N, Turk V, Lah TT . 1997 Clin. Exp. Metastasis 15: 368–381
Hirai K, Yokoyama M, Asano G, Tanaka S . 1999 Hum. Pathol. 30: 680–686
Iacobuzio-Donahue CA, Shuja S, Cai J, Peng P, Murnane MJ . 1997 J. Biol. Chem. 272: 29190–29199
Keppler D, Sameni M, Moin K, Mikkelsen T, Diglio CA, Sloane BF . 1996 Biochem. Cell Biol. 74: 799–810
Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, Terao T . 1993 Biochim. Biophys. Acta. 1178: 55–62
Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T . 1992 Cancer Res. 52: 3610–3614
Kolkhorst V, Sturzebecher J, Wiederanders B . 1998 J. Cancer Res. Clin. Oncol. 124: 598–606
Kostoulas G, Lang A, Nagase H, Baici A . 1999 FEBS Lett. 455: 286–290
Krueger S, Haeckel C, Buehling F, Roessner A . 1999 Cancer Res. 59: 6010–6014
Lah TT, Kos J . 1998 Biol. Chem. 379: 125–130, 1998
Liotta LA, Steeg PS, Stetler-Stevenson WG . 1991 Cell 64: 327–336
Maguire TM, Shering SG, Duggan CM, McDermott EW, O'Higgins NJ, Duffy MJ . 1998 Int. J. Biol. Markers 13: 139–144
McCormick D . 1993 Neuropathol. Appl. Neurobiol. 19: 146–151
Mikkelsen T, Yan PS, Ho KL, Sameni M, Sloane BF, Rosenblum ML . 1995 J. Neurosurg. 83: 285–290
Mohanam S, Chintala SK, Go Y, Bhattacharya A, Venkaiah B, Boyd D, Gokaslan ZL, Sawaya R, Rao JS . 1997 Oncogene 14: 1351–1359
Navab R, Mort JS, Brodt P . 1997 Clin. Exp. Metastasis 15: 121–129
Nygaard SJ, Pedersen PH, Mikkelsen T, Terzis, Tysnes OB, Bjerkvig R . 1995 Invasion Metastasis 15: 179–188
Pedersen PH, Marienhagen K, Mork S, Bjerkvig R . 1993 Cancer Res. 53: 5158–5165
Rempel SA, Rosenblum ML, Mikkelsen T, Yan PS, Ellis KD, Golembieski WA, Sameni M, Rozhin J, Ziegler G, Sloane BF . 1994 Cancer Res. 54: 6027–6031
Schmitt M, Janicke F, Graeff H . 1992 Fibrinolysis 6: 3–26
Sinha AA, Quast BJ, Wilson MJ, Reddy PK, Gleason DF, Sloane BF . 1998 Anat. Record 252: 281–289
Sivaparvathi M, Yamamoto M, Nicolson GL, Gokaslan ZL, Fuller GN, Liotta LA, Sawaya R, Rao JS . 1996 Clin. Exp. Metastasis 14: 27–34
Sivaparvathi M, Sawaya R, Wang SW, Rayford A, Yamamoto M, Liotta LA, Nicolson GL, Rao JS . 1995 Clin. Exp. Metastasis 13: 49–56
Spiess E, Bruning A, Gack S, Ulbricht B, Spring H, Trefz G, Ebert W . 1994 J. Histochem. Cytochem. 42: 917–929
Strojnik T, Kos J, Zidanik B, Golouh R, Lah T . 1999 Clin. Cancer Res. 5: 559–567
Van Noorden CJ, Jonges TG, Van Marle J, Bissell ER, Griffini P, Jans M, Snel J, Smith RE . 1998 Clin. Exp. Metastasis 16: 159–167
Werle B, Lotterle H, Schanzenbacher U, Lah TT, Kalman E, Kayser K, Bulzebruck H, Schirren J, Krasovec M, Kos J, Spiess E . 1999 Br. J. Cancer 81: 510–519
Acknowledgements
We thank Lydia Soto for preparing and Walter J Pagel for reviewing the manuscript. This work was supported by National Cancer Institute Grants CA 76350 (to JS Rao) and P30 CA-16672.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mohanam, S., Jasti, S., Kondraganti, S. et al. Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 20, 3665–3673 (2001). https://doi.org/10.1038/sj.onc.1204480
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204480
Keywords
This article is cited by
-
Mesenchymal stem cells: a trojan horse to treat glioblastoma
Investigational New Drugs (2023)
-
PPARα agonist Wy14643 suppresses cathepsin B in human endothelial cells via transcriptional, post-transcriptional and post-translational mechanisms
Angiogenesis (2013)
-
Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion
Molecular Cancer (2012)
-
A QM/MM study of the binding of RAPTA ligands to cathepsin B
Journal of Computer-Aided Molecular Design (2011)
-
Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas
Laboratory Investigation (2008)